What is Mclab?
Based in South San Francisco, Mclab operates as a specialized biotechnology entity providing critical infrastructure for genomic and proteomic research. The company maintains a comprehensive portfolio that spans DNA sequencing, PCR cloning, and next-generation sequencing (NGS) services, alongside a proprietary suite of enzymes and purification kits. By serving as a foundational partner for researchers and life science professionals, Mclab facilitates high-precision genetic analysis and manipulation. Its market position is defined by a commitment to high-quality laboratory reagents and technical services, which are essential for modern advancements in biotechnology and clinical diagnostics.
How much funding has Mclab raised?
Mclab has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Mclab
PPP
Public-Private Partnership
What's next for Mclab?
With the infusion of $150K, Mclab is expected to prioritize the scaling of its laboratory infrastructure and the enhancement of its R&D pipeline. The company's late-stage funding status suggests a transition toward broader market penetration and the potential optimization of its supply chain for high-throughput sequencing services. Strategic focus will likely remain on maintaining technical superiority in molecular biology tools while exploring new avenues for commercial growth in the rapidly evolving genomics landscape. As the firm matures, the integration of advanced automation and expanded service offerings will be pivotal in sustaining its competitive advantage and driving long-term value for stakeholders in the life sciences ecosystem.
See full Mclab company page
